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Background-—Although frailty has been associated with increased risks for hospitalization and mortality in chronic heart failure,
the precise average effect remains uncertain. We performed a systematic review and meta-analysis to summarize the hazards for
mortality and incident hospitalization in patients with heart failure and frailty compared with those without frailty and explored the
heterogeneity underlying the effect size estimates.
Methods and Results-—MEDLINE, EMBASE, and Cochrane databases were queried for articles published between January 1966
and March 2018. Predefined selection criteria were used. Hazard ratios (HRs) were pooled for meta-analyses, and where odds
ratios were used previously, original data were recalculated for HR. Overlapping data were consolidated, and only unique data
points were used. Study quality and bias were assessed. Eight studies were included for mortality (2645 patients), and 6 studies
were included for incident hospitalization (2541 patients) during a median follow-up of 1.82 and 1.12 years, respectively. Frailty
was significantly associated with an increased hazard for mortality (HR, 1.54; 95% confidence interval, 1.34–1.75; P<0.001) and
incident hospitalization (HR, 1.56; 95% confidence interval, 1.36–1.78; P<0.001) in chronic heart failure. The Fried phenotype
estimated a 16.9% larger effect size than the combined Fried/non-Fried frailty assessment for the end point of mortality (HR,
1.80; 95% confidence interval, 1.41–2.28; P<0.001), but not for hospitalization (HR, 1.57; 95% confidence interval, 1.30–1.89;
P<0.001). Study heterogeneity was found to be low (I2=0%), and high quality of studies was verified by the Newcastle-Ottawa
scale.
Conclusions-—Overall, the presence of frailty in chronic heart failure is associated with an increased hazard for death and
hospitalization by 1.5-fold. ( J Am Heart Assoc. 2018;7:e008251. DOI: 10.1161/JAHA.117.008251)
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F railty is a complex systemic syndrome that has beenassociated with poor outcomes, including increased
rates of mortality and hospitalization in frail patients with
heart failure (HF) compared with those without frailty.1–7 More
commonly observed in association with advanced age,1 frailty
can also affect young patients with HF and can be reversible
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after heart transplantation8 or heart function replacement.9
Characterizing frailty status in patients with HF may provide
clinicians an indicator for gauging disease severity, prognosis,
and disease progression or reversal.
Although most studies have shown increased risks for
hospitalization and mortality in chronic HF,2–7 offset by 2
relatively small studies with borderline neutral results,10,11 the
precise average effect of frailty has not previously been
summarized with certainty. Recently, a systematic review
included a total of 8 articles from 2004 to 2014 and suggested
that patients with HF and frailty had increased risks for adverse
outcomes.12 However, 2 of 8 articles5,13–15 in that study
contained data from overlapping studies (ie, double counting),
and no meta-analysis was performed. Since 2014, 6 additional
independent studies2–4,11,16,17 with potential to be included in a
meta-analysis have been published. Recently, a systematic
review and meta-analysis has summarized data on the preva-
lence of HF-associated frailty from 26 studies at 44.5% after
removal of 14 overlapping studies.18 However, that study did
not assess the impact or effect size of frailty on adverse
outcomes, including death and hospitalization, and included
patients with acute HF and those receiving cardiac resynchro-
nization therapy, left ventricular assist device (LVAD), or heart
transplant.18 In this study, we have carefully summarized the
existing evidence, explored for heterogeneity, and completed
the first meta-analysis of frailty on the hazards of mortality and
incident hospitalization in patients with chronic HF.
Methods
Data Sources and Search Strategy
The data that support the findings of this study are available
from the corresponding author on reasonable request. From
October 2016 to April 2018, we searched MEDLINE, EMBASE,
and the Cochrane databases for articles published between
January 1966 and March 2018. Study design (Figure 1 and
Figure S1) and data reporting were compliant with MOOSE, as
recommended in the EQUATOR Network guidelines.19,20
Institutional Review Board approval was not required for this
systematic review and meta-analysis.
Eligibility Criteria
The following Medical Subject Headings or MeSH search
terms were used: “frailty AND heart failure,” “frail AND heart
failure,” “fragility AND heart failure,” “gait speed AND heart
failure,” “grip strength AND heart failure,” “weight loss AND
heart failure,” and “cognitive frailty AND heart failure.”
Fragility is a term used by some European investigators with
whom we have individually confirmed about its use in their
publications as being synonymous with frailty for the purpose
of this study. Literature search was independently performed
by 2 reviewers (E.F. and X.Y.), according to a prespecified
workflow. Conflicting findings were resolved by a third
researcher (J.W.). The inclusion criteria were as follows:
(1) frailty assessed using validated assessment instruments;
(2) confirmed diagnosis of HF on the basis of international
criteria and guideline definitions21,22; (3) human individuals;
and (4) articles in English. The exclusion criteria were as
follows: (1) unpublished data, abstracts, conference proceed-
ings, comments, letters, correspondences, editorials, or dupli-
cates; (2) studies without any relevance to the clinical outcomes
of hospitalization and mortality; (3) studies that investigated the
effects of medical or surgical intervention, including cardiac
resynchronization therapy, LVAD, and cardiac transplantation;
(4) data on acute HF; and (5) non-English articles.
Data Extraction
The main clinical outcomes in this meta-analysis were all-
cause mortality and hospitalization. Where data on all-cause
hospitalization were not available,3 cardiac hospitalization
Clinical Perspective
What Is New?
• This meta-analysis is the first to summarize the literature
and report on a 1.5-fold increase in the adverse outcome of
death or incident hospitalization associated with frailty in
patients with chronic heart failure during a follow-up of
<2 years.
• The Fried phenotype, an often-used frailty assessment scale
originally developed from the Cardiovascular Health Study,
estimated a higher mortality rate of 16.9% compared with
that of the combined (Fried and non-Fried) assessment,
whereas the estimate for incident hospitalization was
indistinct between Fried and the combined assessments.
What Are the Clinical Implications?
• Since publication of “Knowledge Gaps in Cardiovascular
Care of the Older Adult Population: A Scientific Statement
From the American Heart Association, American College of
Cardiology, and American Geriatrics Society” (2016), and
the Geriatric Cardiology Council document of the American
College of Cardiology (2018), there have been increasing
efforts to tackle heart failure and geriatric cardiovascular
disease using multidomain approaches.
• The Fried phenotype is simple to use, provides prognostic
information, and assesses for domain-based physiological
insufficiencies that may lend itself to daily clinical practice
and screening for latent chronic heart failure.
• Frailty associated with heart failure may be reversible and a
target for intervention.
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was used. A structured data form was used to organize
information2–7,10,11,13–17,23–37 (Table). Two reviewers (E.F. and
X.Y.) extracted the raw data and independently evaluated
study quality (described later).
Data Synthesis and Statistical Analysis
The effect sizes of risks were reanalyzed and recalculated as
hazards, pooled, and represented by adjusted or unadjusted
hazard ratios (HRs) for the clinical outcomes of all-cause
mortality or hospitalization in frail and nonfrail patients with
chronic HF. When available, all-cause rather than cardiac
hospitalization was used. This is justified by evidence in the
literature that hospitalizations secondary to HF with preserved
left ventricular ejection fraction (EF) are often attributable to
complex comorbidities.21,22 Of 6 studies included in the meta-
analysis of frailty on incident hospitalization, 5 used all-cause
hospitalization and 1 used cardiac hospitalization3 as end
points. Where possible, adjusted, rather than unadjusted, HRs
were used (Table S1).
To standardize classification of frailty/nonfrailty status,
we reclassified prefrailty, a nonexistent category in some
frailty assessment scales,38,39 as nonfrailty. To minimize
data redundancy and double counting,40 we contacted
authors of the original studies for clarification and data
reanalysis, where necessary. Among a total of 10 groups
authoring 20 studies, 8 groups responded to our query with
clarification and/or assisted in reanalysis (response rate,
80%). Where data redundancy from overlapping studies was
suspected or in cases in which the original authors could
not be reached, we proceeded to remove those articles
from further analysis. The research group of Bayes-Genıs,
Lupon, and Gastelurrutia consolidated their cohort data
from 3 publications and reanalyzed risk estimates.3,15,34
Originally presented as odds ratios in the study of Vidan
and colleagues,4 the risk for rehospitalization was recalcu-
lated as HRs using data from telephone interviews at 1, 3,
6, and 12 months after hospital discharge. For 66 patients
in that study who did not have the exact dates of
rehospitalization, the time to hospitalization was imputed
using the calculated mean time to hospitalization from the
remaining 340 patients. The data on mortality and hospi-
talization from the original article by Ferguson and





245 full-text articles screened
28 eligible articles 
19 unique studies 
8 unique studies on
mortality 
6 unique studies on
hospitalization
6641 records excluded:
4659 irrelevant articles 
1357 duplicates 
625 conference proceedings or abstracts 
217 studies excluded:
196 did not meet inclusion criteria
21 interventional studies – CRT, LVAD, or 
heart transplant
9 studies excluded:
Overlapping or redundant data
10 studies excluded:
7 insufficient data on clinical end points 
3 original source data unavailable for 
reanalysis
9 unique studies with with





Data on mortality 
unavailable
Figure 1. Study identification and selection. CRT indicates cardiac resynchronization therapy; LVAD, left
ventricular assist device.
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Results from eligible studies were pooled and meta-
analyzed using a random-effects model with inverse-variance
weighting. Heterogeneity of studies was assessed using
Cochrane’s Q statistic and I2. Prespecified I2 threshold values
of 25%, 50%, and 75% were used to indicate low, moderate,
and high levels of heterogeneity, respectively. A 2-tailed
P<0.05 was considered statistically significant. Analyses were
performed using Review Manager 5.3 (The Cochrane Collab-
oration) and R 3.3.3 (R Foundation).
Assessment of Publication Bias and Study Quality
Publication bias was assessed using funnel plots and Duval-
Tweedie’s trim-and-fill test (Figure S2).
Results
Search and Study Selection
Our query to EMBASE, MEDLINE, and Cochrane databases
returned 6886 records (Figure 1 and Figure S1). After
further screening and evaluation, 6641 irrelevant records
and 217 ineligible full-text articles were excluded. Among
28 eligible articles,2–7,10,11,13–17,23–37 8 and 6 unique
studies were finally included in the meta-analysis for all-
cause mortality and incident hospitalization, respectively
(Figure 1 and Table).
Characteristics of Patients With Chronic HF
Among studies that reported on the prevalence rates of atrial
fibrillation, ischemic heart disease (coronary artery disease),
hypertension, and/or diabetes mellitus, the respective
median prevalence rates were 53% (quartile 1–quartile3,
46.5%–62.2%), 44.5% (quartile 1–quartile 3, 26.9%–54.5%),
80% (quartile 1–quartile 3, 64.0%–87.9%), and 38.4% (quartile
1–quartile 3, 34.8%–47.0%). The median prevalence rate of
frailty from 17 of 19 nonoverlapping studies was 49.0%
(quartile 1–quartile 3, 21.7–64.9); data were unavailable from
2 studies.
Frailty Is Significantly Associated With Increased
Mortality in Chronic HF
On the basis of data from 8 unique studies, the presence
of frailty is significantly associated with an increased
hazard for mortality in chronic HF (HR, 1.54; 95%
confidence interval [CI], 1.34–1.75; P<0.001) (Figure 2A
and Table S2). The median duration of follow-up for 2645
patients in the 8 studies2–6,10,11,16 was 1.82 years (quartile
1–quartile 3, 1.0–3.9 years). In studies that used only the
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Figure 2B), the effect size estimate was increased by 16.9%
(HR, 1.80; 95% CI, 1.41–2.28; P<0.001; n=1127
patients).2,4,5,10,11 Irrespective of the frailty assessment
instrument used, the level of study heterogeneity was low
(I2=0%) (Figure 2A and 2B).
Frailty Is Significantly Associated With an
Increased Rate of Hospitalization in Chronic HF
During a median follow-up of 1.12 years (quartile 1–quartile





Figure 2. Eight unique studies with nonoverlapping data. Inverse variance (IV) weighting and random-effects model were used in the meta-
analysis. Reference number is shown after year of publication (see References for details). A, Effects of frailty on all-cause mortality in patients
with chronic heart failure (HF). B, Effects of frailty on all-cause mortality in patients with chronic HF in 5 studies that used the Fried phenotype
for frailty assessment. IV weighting and random-effects model were used in the meta-analysis. Reference number is shown after year of
publication (see References for details). C, Effects of frailty on incident hospitalization in patients with chronic HF. Six unique studies with
nonoverlapping data are shown. IV weighting and random-effects model were used in the meta-analysis. Reference number is shown after year
of publication (see References for details). D, Effects of frailty on incident hospitalization in patients with chronic HF in 4 studies that used the
Fried phenotype for frailty assessment. IV weighting and random-effects model were used in the meta-analysis. Reference number is shown
after year of publication (see References for details). CI indicates confidence interval; df, degrees of freedom; HR, hazard ratio.
DOI: 10.1161/JAHA.117.008251 Journal of the American Heart Association 7
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associated with an increased hazard for hospitalization by
56% (adjusted HR, 1.56; 95% CI, 1.36–1.78; P<0.001; n=2541
patients in 6 studies), even after adjusting for factors in the
respective studies2–4,7,11,16 (Figure 2C and Table S1). In 4
studies that used Fried assessment,2,4,7,11 the estimate was,
however, similar (adjusted HR, 1.57; 95% CI, 1.30–1.89;
P<0.001; n=1142 patients) to the overall pooled estimate
(Figure 2D). The level of heterogeneity between studies was
also low (I2=0%) (Figure 2C and 2D).
Publication Bias and Study Quality
Although the effect size estimates for mortality fell within the
pseudo 95% confidence limits of the funnel plot (Figure S2A),
we proceeded to using the trim-and-fill test for ascertainment
and found no significant difference with or without adjustment
(adjusted HR, 1.48 [95% CI, 1.25–1.75] [P<0.001] 1.54 [95%
CI, 1.34–1.75] [P<0.001]) (Figure S2C and Figure 2A), thereby
ruling out large publication bias effects. The high quality of the
included studies2–7,10,11,16 was indicated by a composite
score of ≥7 on the Newcastle-Ottawa scale41 (Table S3).
Discussion
Frailty is increasingly recognized as an important target for
monitoring and intervention in contemporary cardiovascular
care and management.42,43 Clinical pathways using frailty
assessment in management decision making and for determi-
nation of procedural eligibility have previously been shown to
affect patient outcomes and provide prognostic indication of
well-being and survival associated with procedures, ranging
from transcatheter and surgical aortic valve replacement to
heart transplantation.43–45 However, the precise negative
effects of frailty on chronic HF2–7,10,11 have not been previously
established with certainty.
This systematic review and meta-analysis is the first to
summarize the adverse impact of hospitalization and mortality
associated with frailty in chronic HF. Mortality and incident
hospitalization were both significantly increased by 1.5-fold
in >1300 patients with HF with frailty, compared with >1200
patients with HF without frailty (Figure 2). This study has
reanalyzed and recalculated risk estimates as HRs, consoli-
dated data from 3 independent sources (study cohorts from
Barcelona, Spain; Madrid, Spain; and Sydney, Australia) to
minimize or eliminate double counting, and focused on
patients with chronic HF. Current available studies in the
literature have not included any meta-analyzed data on
mortality and hospitalization associated with frailty in HF,12,46
and frailty prevalence was the sole focus of another recently
published meta-analysis that included patients with acute
decompensated HF, patients with chronic HF, and patients
receiving cardiac resynchronization therapy, LVAD, and heart
transplant.18
One of themajor findings in this study was the higher estimate
of hazard for mortality, but not incident hospitalization, by the
Fried phenotype compared with the overall pooled (combined
Fried and non-Fried) estimates (Figure 2). The reason for this
observation is unclear, but it can be possibly explained by the
overlapping characteristics (and pathophysiological features)
between functional components of the Fried phenotype (eg,
progressive unintentional weight loss and weakness) and cardiac
cachexia of advanced chronic HF, which carries a poor prognosis.
However, the concept of cardiac cachexia cannot be simply
explained by reduced body mass index alone because this
relationship is complex,43 depending on the population or patient
subsetwithHF, the cause, thepathogenesis, and the chronicity of
the pathophysiological features. For instance, patientswaiting for
heart transplant tend to be younger, may have developed HFwith
reduced EF over a relatively shorter period (eg, post–viral dilated
cardiomyopathy), and may have different physiological reserve
levels and body composition compared with elderly patients with
long-standing, chronic HF. Older adults may have more
comorbidities,47 latent chronic HF48 (particularly, HF with pre-
served EF), and sarcopenic obesity,49 a disorder characterized
by low lean skeletal muscle mass relative to abundant intermus-
cular adiposity. This meta-analysis was focused on patients with
chronic HF and frailty outside the setting of heart function
replacement or acute HF, acknowledging the variability in pheno-
typic expressionof (or individuals’ variable resistance to) frailty, and
its manifestation and reversibility across the HF spectrum.
The clinical phenotype proposed by Fried and colleagues38 in
2001 is based on the concept of aging-related failure of
homeostasis in physiologic systems (or domains) represented
by 5 specific items: low physical activity, fatigue, shrinkage (or
unintentional weight loss over a defined period), weakness, and
slowness. The 5 items of the Fried phenotype are scored out a
total of 5 points, with 1 point awarded for each positive item;
scores of ≥3, 1 to 2, and 0 indicate subjects in frail, prefrail, and
robust states, respectively. The prefrail state may be a clinically
relevant indicator of underlying cardiometabolic disorder,
reduced physiological reserve, and a window of opportunity for
workup and intervention before development of systemic
decompensation. However, the absence of prefrailty in some
frailty assessment scales precluded comparison between studies
for this condition. Another major frailty concept is centered on
the frailty index developed by Rockwood et al.50 The frailty index
is based on a cumulative multiple deficit approach, using clinical
and laboratory variables with an emphasis on the number rather
than type of derangements. As noted, these and other commonly
used frailty assessment tools, including themodified Fried-based
FRAIL scale that obviates physical testing (eg, hand grip strength
and walking tests51) with improved clinical operationality, have
been previously compared in specific settings and found to
DOI: 10.1161/JAHA.117.008251 Journal of the American Heart Association 8
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perform similarly.51,52 Other surrogate markers of frailty include
gait speed,53,54 which has been reported to offer prognostic
information in patients with HF.55 Our search strategy in this
study has included individual components of frailty assessment
scales (see Methods) to maximize identification of articles in the
literature.
A major challenge lies in the harmonization of a wide range of
frailty assessment scales used in studies. Woo and coworkers
havepreviously reported that themajor frailty scales (frailty index
by Rockwood and Mitnitski, Fried phenotype from the Cardio-
vascular Health Study, FRAIL scale, and the Hubbard modified
frailty score) perform similarly in predicting death and physical
limitation in a geriatric study population.51 Chong and colleagues
found that several frailty assessment instruments (frailty index,
FRAIL scale, Tilburg Frailty Index, andClinical Frailty Scale) tested
did not significantly differ in their ability to diagnose frailty.52
Those findings suggest that pooling of studies for meta-analysis
can be feasible and informative for the specific purpose of this
study, as supported by available evidence in the literature.
HF and aging-related frailty share common signs, symptoms,
and manifestations, including sarcopenia or skeletal muscle
weakness, impaired cardiorespiratory and physical fitness,
increased inflammatory burden,56 and central nervous system
dysfunction.57,58 Although definitions and assessment scales
do vary, there has been impetus toward a universal definition of
frailty in the geriatric professional community.1,59,60 Currently,
frailty is not routinely assessed for or systematically catego-
rized in patients with HF.1,21,22,42,61 However, findings from this
and other studies encourage the use of frailty assessment for
risk stratification of patients with HF to inform prognosis and
management decisions. Recent data from the LVAD and heart
transplant literature suggest that frailty in patients with
advanced HF can be reversed by intervention or organ
replacement8,43 and that frailty is not necessarily age or
functional class related,18 suggesting that inclusion of frailty
assessment in patients with HF can inform outcomes. Indeed,
Jha and colleagues have shown that pre-LVAD or pretransplant
frailty status has a significant impact on survival after LVAD
implantation or heart transplantation.43
There are several limitations in this study. First, the compet-
ing risks betweenhospitalization andmortality across time could
not be assessed given the limitations inherent in the original
studies.62 Second, hospitalization as an outcome measure is
complex andmay beHF associated, cardiac related, or unrelated
to cardiovascular events.63,64 Details on hospitalization and
contemporary metrics (eg, 30-day readmission and length of
stay) for characterizing hospitalization were unavailable from the
included studies. Future studies using standardizedmetrics may
improve accuracy of risk estimates. Third, therewere insufficient
data in the available articles to perform a meta-analysis on HF
subtypes (eg, HFwith reducedEF andHFwith preserved EF).21,22
Although some studies have shown that the adjusted survival
and hospitalization rates are similar between HF subtypes,47,65
there is a need for future studies to clarify this.
In conclusion, this meta-analysis provides the first sum-
mary on the effects of frailty on mortality and hospitalization
and confirms the significant negative impact of frailty on
chronic HF. Stratification of patients with HF by frailty status
provides prognostic information and may inform priorities for
HF interventions and management.
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Table S1. List of covariates adjusted for in calculating hazard ratios (adjusted 
hazard ratios). 
 
Source (First Author [PMID]Ref.)* Covariates 
Boxer [20887617]1 Age, high-sensitivity C-reactive protein, interleukin-6 
Cacciatore [16316247] 2 Age, sex, NYHA class, comorbidity, systolic and diastolic blood 
pressure, HF etiology (i.e. ischemic vs. others), use of diuretics, 
ACEI, digoxin and nitrates 
Ferguson [27036952]3 N/A (only unadjusted hazard ratio available) 
Gastelurrutia [24820761]4 Age, sex, HF duration, HF etiology, HF hospitalization, LVEF, 
NYHA class, number of comorbidities, history of implantable 
cardioverter defibrillator, use of beta-blockers, ACEI/ARB, 
mineralocorticoid receptor antagonist, loop diuretics and statin  
Madan [26883168]5 Age, sex, diabetes mellitus, Charlson comorbidity index 
McNallan [23956958]6 Age, sex, LVEF, incident and prevalent HF, estimated glomerular 
filtration rate, history of chronic obstructive pulmonary disease, 
diabetes mellitus and anemia 
McNallan [24093859]7 Age, sex, LVEF 
Rodríguez-Pascual [28215465]8 Age, sex, Charlson comorbidity index, LVEF ≤45%, previous HF-
related hospitalization other than the index admission, use of 
ACEI/ARB and beta-blocker 
Vidán [27072307]9 Age, sex, acute and chronic comorbidities, LVEF, NYHA class, N-
terminal pro B-type natriuretic peptide level 
ACEI, Angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; HF, heart failure; 
LVEF, left ventricular ejection fraction; N/A, not applicable; NYHA, New York Heart Association. 
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Table S2. Actual numbers of deaths and/or hospitalization episodes in chronic heart failure patients with and without frailty. 
 





Mortality, % (n)  Hospitalization, % (n) 
Total  Frail  Non-frail  Total  Frail  Non-frail 






































































































































N/A, not applicable. PMID, PubMed identifier. Ref., reference number 
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Selection Comparability Outcome 
Source (First 















of interest was 
not present at 
start of study 
Score 
Subtotal 
Comparability of cohorts on the 













Boxer [20887617]1 2010 8 3 0 1 1 1 2 Frailty (age, interleukin-6, 
high-sensitivity C-reactive 
protein) 
3 1 1 1 
Cacciatore 
[16316247]2 
2005 9 4 1 1 1 1 2 Frailty (age, sex, NYHA, 
blood pressure, 
comorbidity, HF etiology, 
use of ACEI, digoxin, 
diuretics and/or nitrates)  
3 1 1 1 
Ferguson 
[27036952]3 
2017 7 4 1 1 1 1 0 Not applicable 3 1 1 1 
Gastelurrutia 
[24820761]4 
2014 9 4 1 1 1 1 2 Fragility† (age, sex) 3 1 1 1 
Madan [26883168]5 2016 8 3 1 1 1 0 2 Frailty (age, sex, DM, 
Charlson comorbidity 
index) 
3 1 1 1 
McNallan 
[23956958]6 
2013 8 3 1 1 1 0 2 Frailty (age, sex, LVEF, 
incident HF and prevalence 
of HF, estimated glomerular 
filtration rate, chronic 
obstructive pulmonary 
disease, DM, anemia) 
3 1 1 1 
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ACEI, angiotensin converting enzyme inhibitor; DM, diabetes mellitus; HF, heart failure; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal prohormone 
of brain (B-type) natriuretic peptide; NYHA, New York Heart Association functional class. 
*Newcastle-Ottawa Scale categorizes the quality of a study based on summed total points: low, 0 to 3 points; intermediate, 4 to 6 points; high, 7 to 9 points. 
†Fragility is synonymous with frailty in this study. 













2017 9 4 1 1 1 1 2 Frailty (age, sex, Charlson 
index, LVEF ≤45%, 
previous HF-related 
hospitalization other than 
the index admission, use of 
ACEI or angiotensin 
receptor blocker and β-
blocker) 
3 1 1 1 
Vidán [27072307]9 2016 9 4 1 1 1 1 2 Frailty (age, sex, acute and 
chronic comorbidities, 
LVEF, NYHA, NT-proBNP 
levels)  








Figure S1. Detailed CONSORT-style flow diagram. PubMed unique identifiers 

























































Figure S2. Funnel plots assessing for publication bias in the meta-analyses of 
frailty on (A) all-cause mortality and (B) incident hospitalization in patients with 
chronic heart failure. (C) Data on all-cause mortality were further subjected to the 
Duval-Tweedie’s trim and fill test, demonstrating virtually unchanged effect size 
estimates and statistical significance (adjusted hazard ratio, 1.48; 95% confidence 
interval 1.25–1.75, P<0.001). 
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